Stiefel has received approval from the Food and Drug Administration for Fabior Foam (tazarotene 0.1%), an acne treatment.


Stiefel, Fabior Foam, tazarotene 0.1%, acne treatment, GlaxoSmithKline, topical foam, moderate-to-severe acne, acne vulgaris, Jean-Christophe May, dermatology, skin problem




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Stiefel cleared to market acne foam

May 14th, 2012

RESEARCH TRIANGLE PARK, N.C. – Stiefel has received approval from the Food and Drug Administration for Fabior Foam (tazarotene 0.1%), an acne treatment.

The GlaxoSmithKline subsidiary said Friday evening that Fabior Foam is the only retinoid in a topical foam formulation for the treatment of acne vulgaris in people age 12 and older.

"Stiefel is dedicated to meeting the needs of patients and dermatologists, and we believe Fabior Foam will be an important treatment option for people with moderate-to-severe acne," stated Jean-Christophe May, vice president, North America Dermatology.

Acne is the nation's most common skin problem, affecting about 40 million to 50 million Americans — primarily adolescents and young adults — at any one time, according to the American Academy of Dermotology.

Advertisement